|
|
HIV Update 2001 (3) - The impact of resistance testingPublished by: Datamonitor Published: Oct. 15, 2001 - 50 Pages Table of ContentsEXECUTIVE SUMMARY Datamonitor insight into the HIV Market Datamonitor insight into the resistance testing market CHAPTER 2 ANALYSIS OF KEY Q3 DEVELOPMENTS KEY HEADLINE - Collaboration between ViroLogic and Triangle announced to develop new anti-HIV drugs using resistance testing COMPANY HEADLINES GSK announce profit increase from 2000 Efficacy tests for VaxGen's AIDSVAX Par Pharmaceutical Receives Final Approval of Anti-Weight Loss Drug for AIDS Patients Agouron Vaunts Viracept Success Ichor Emphasises Shift into HIV with New Name Viread FDA Review Date Announced RESEARCH AND DEVELOPMENT HEADLINES Vaccine First for HIV like Virus Prophylaxis Phase III Trial Enrolment Complete for T-20 Hope for Entry Inhibitor From the Whitehead Institute WHI-07 Shows Promise as Dual Anti-HIV Agent and Contraceptive CEL-SCI HIV Vaccine Looks Promising DISEASE SPECIFIC HEADLINES AIDS Therapy Interruptions Could Work Viral Load Spikes Not Indicative of Drug Failure Virco Test Predicts Resistance Over Two Year Period Skin Abnormalities in HIV Patients Blamed on Newer Anti-Retrovirals EMERGING MARKETS HEADLINES Cipla Cuts Prices for Fourth Time in Nine Months BMS Accused of Stalling on HIV Drug Offer Chiron Sizes Up India For AIDS Vaccine Supply GSK's offer of cheap drugs declined in South Africa Roche Submits to Brazilian Demands Emerging Market Seeks Generic Partners CHAPTER 3 RESISTANCE TESTING 3.1 Introduction What is resistance testing? Market impact of resistance testing on HIV treatment Market impact of resistance testing on the pharmaceutical industry Types of resistance testing 3.2 Market Focus Current market conditions and resistance testing sales in the US Current market conditions and resistance testing in Europe Current US market leaders in phenotypic resistance testing Genotypic resistance tests currently marketed in the US 3.3 Case Study 1: Virco and ViroLogic's competition in the resistance testing market 3.4 Case Study 2: BioAlliance's entry into the resistance testing market 3.5 Impact of resistance testing on the pharmaceutical industry Impact by drug class 3.6 Possibilities for pharmaceutical company collaboration with resistance test manufacturers 3.7 Strategies available for the pharmaceutical industry 3.8 Future focus Future of the resistance testing market Future impact on the pharmaceutical market Potential for collaboration between resistance test manufacturers and pharmaceutical companies (c) Datamonitor 2001. All Rights Reserved. AbstractThis Review provides an analysis of the key developments that have occurred in the HIV market in Quarter III. In addition, it provides an insight into the impact of resistance testing on the pharmaceutical industry. Increasing clinical usage of resistance testing is creating a growing commercial interest in patenting such tests. Although the market is expected to grow between 2001 and 2006, competition between test manufacturers will become increasingly intense. Opportunities exist for the pharmaceutical industry to benefit from the changing trends in the resistance testing market. Collaboration with resistance test manufacturers may allow pharmaceutical companies to use resistance testing data to promote existing drugs, or, in developing pipeline drugs, to target patient populations showing resistance profiles that favor their product.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||